Real-World Studies
Emerging ESR1 Mutations Linked to Reduced Survival in ER+/HER2- Metastatic Breast Cancer
Meisel et alBreast Cancer Research and Treatment
A retrospective observational cohort study analyzing real-world data from 7,772 patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer evaluated the clinical significance of emerging estrogen receptor 1 (ESR1) mutations during first-line (1L) therapy. Utilizing the US-based Flatiron Health Research Database between 2018 and , researchers assessed treatment patterns and clinical outcomes among patients tested for ESR1 mutations during 1L therapy, comparing 240 patients with detected ESR1 mutations against 1,095 patients without detectable mutations.
First-line treatment selection was comparable between patients with and without detected ESR1 mutations. However, detection of an ESR1 mutation during 1L therapy was associated with significantly inferior real-world progression-free survival (rwPFS) and real-world overall survival (rwOS) measured from the time of first ESR1 testing to minimize time-related bias. Following propensity score matching, detection of ESR1 mutations remained significantly associated with shorter rwPFS (hazard ratio [HR]: 0.68; 95% CI: 0.48–0.96) and rwOS (HR: 0.58; 95% CI: 0.36–0.95). These findings highlight that early emergence of ESR1 mutations prior to clinical disease progression signifies endocrine resistance and predicts compromised survival outcomes.
Key Takeaways
- In patients with ER+/HER2- metastatic breast cancer tested during first-line therapy, detection of an ESR1 mutation was associated with significantly shorter real-world progression-free survival compared to those without detected mutations (rwPFS HR: 0.68; 95% CI: 0.48–0.96).
- Emergent ESR1 mutation detection during first-line treatment was significantly associated with worse real-world overall survival following propensity score matching (rwOS HR: 0.58; 95% CI: 0.36–0.95).
- First-line treatment selection was comparable between patients with (n = 240) and without (n = 1,095) ESR1 mutations detected during first-line therapy within the evaluated population.
Read the original sourceBreast Cancer Research and Treatment
